NDC product
Acetazolamide
NDC 23155-831 · Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Key facts
| Product NDC | 23155-831 |
|---|---|
| Proprietary name | Acetazolamide |
| Nonproprietary name | Acetazolamide |
| Substances | ACETAZOLAMIDE SODIUM |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA202693 |
| Pharmacologic classes | Carbonic Anhydrase Inhibitor [EPC], Carbonic Anhydrase Inhibitors [MoA], Sulfonamides [CS] |
| Marketing start | Nov 15, 2022 |
| Marketing end | Sep 30, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory